Isarna gets $18M for antisense turnaround

By Cormac SheridanStaff Writer

Tuesday, January 7, 2014

Isarna Therapeutics GmbH raised €13 million (US$17.7 million) in new investments and has secured access to a new chemistry platform to take a fresh stab a developing antisense inhibitors of transforming growth factor-beta (TGF-beta) in oncology indications.